actively trading these days
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All right. Let's light this candle this year!
I'm sure it depends on the drug.
How did you determine that market cap?
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product.
Dec 12, 2023
Elite Pharmaceuticals Announces First Product Shipment Of Generic Adderall XR® To Marketing Partner Prasco, LLC
NORTHVALE, NJ / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced the first shipment of generic Adderall XR® to its distribution and marketing partner Prasco, LLC ("Prasco"). Adderall XR® is an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules (the "Products").
Prasco is, pursuant to the manufacturing and supply agreement dated April 5, 2023 ("Agreement") between the companies, a non-exclusive U.S. distributor of the Products. Prasco will market the Products under Burel Pharmaceutical's label, and Elite will manufacture the Products. Elite's product is co-owned with Mikah Pharma.
About Prasco, LLC
Prasco is a privately held healthcare company located in Mason, Ohio. Over 50 of the most innovative and trusted pharmaceutical companies have relied on Prasco to bring their products to the US generic marketplace. Prasco provides patients with high-quality products at affordable prices in over 60,000 US pharmacies. For more information, visit the company's website at www.prasco.com.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
The tweet told us it was wet weight.
I have been in dozens of OTC stocks over the past 20 years. Many were outright scams. But this one is a legit company with legit products, IMO. However, every OTC company struggles with the financial basics, no matter how legit they are.
Jeffrey has responded within a day to every email I ever sent him. No complaints here on that front.
PR about what?
Looking really good here.
IMO, we close above .16 by Friday and probably hit .17 at least once.
Yep, the RS killed me. But I remain optimistic. Fortunately, I have ELTP to save me.
This is trading well now, but I need it to get to a dollar to break even. LOL.
Wow, that is super significant.
I never understand the trading of this thing at all.
Don't see where you get a number that low, but I seriously doubt it.
So, do we finish in the green or red today? After yesterday's very positive CC, we should finish up, but who knows.
After hearing this CC, I have never been more confident in any stock I have owned in 20 years. We certainly will get to dollarland.
New 52-week high coming in minutes.
I'm not finding a PR or anything in the latest filing re Prasco. Where do I find the details of that deal? TIA.
Back to the ticker BOMO today.
A buyback and reducing AS. Sounds good to me.
Thank you very much. Nice trend there, although not dramatic. So, I predict about $10M for this past quarter.
I figured that one of you have a list of this exact thing at your fingertips. I find annual revenues, but not quarter by quarter.
Could one of you guys/gals, who are on top of this, list the revenues for the past six quarters? I would love to see the progress once again.
But what is the thought on what the buyout price would be? 10-15 cents? Which is what I am afraid of.
Any good news should push us to a quarter.
And we add a 12th MM. Very bullish. It means more orders are coming into more brokers, who use different MMs.
And now, 11 MMs. This is really getting good. More orders, more volume, and you end up with more MMs.
We knew it was coming eventually. We have quadrupled in about a month.
Looks like we have added a 10th MM: PUMA.
I really like the way this is trading. Nice slow climb.
This is holding up much better than most stocks after a RS.
Hike, where you been man?
Someone is chipping away at the ask. Keep it up. I want to see .15 soon.
Geesh. Let's break through this dime barrier and move on.
I think we are moving up today. We hit .11, IMO.
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
NORTHVALE, NJ / ACCESSWIRE / September 25, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products ...
Continue Reading
Yea, that is a different kind of short. Temporary, and usually rectified by the end of the trading day.
I've read those articles and seen those videos. They are crap. I thought this issue was put to rest a decade ago on these boards. But Americans love conspiracy theories.